Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01846182
Other study ID # SPLD-016-12F
Secondary ID 6125
Status Terminated
Phase Phase 2
First received
Last updated
Start date June 24, 2015
Est. completion date August 1, 2019

Study information

Verified date February 2021
Source VA Office of Research and Development
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

At least 1 in 4 of the 700,000 U.S. Veterans who served in the 1990-1991 Gulf War suffer from Gulf War Illness (GWI). Despite considerable research, effective treatments remain elusive. GWI refers to a complex of symptoms that typically include widespread chronic pain, persistent headache, memory and concentration problems, gastrointestinal difficulties, sleep disturbances and unexplained fatigue. These symptoms are similar to that of fibromyalgia syndrome (FMS), another multi-symptom condition. Whereas, effective treatments for GWI have yet to be found, the FDA has approved duloxetine and pregabalin for the treatment of FMS. The lack of progress in finding effective treatments for GWI, and the similarities between GWI and FMS, provides a rationale for determining if these medications can provide relief to Veterans who suffer from GWI. This randomized controlled trial will test the efficacy of Duloxetine and Pregabalin for treating Gulf War Veterans who suffer from GWI.


Description:

At least 1 in 4 of the 700,000 U.S. Veterans who served in the 1990-1991 Gulf War suffer from Gulf War Illness (GWI). Despite considerable research, effective treatments remain elusive. GWI refers to a complex of symptoms that typically include widespread chronic pain, persistent headache, memory and concentration problems, gastrointestinal difficulties, sleep disturbances and unexplained fatigue. This symptom profile is similar to that of fibromyalgia syndrome (FMS), a multi-symptom condition similar to GWI. Whereas, effective treatments for GWI have yet to be found, progress has been made in identifying medications to treat FMS. For example, the FDA has approved a number of medications including Duloxetine and Pregabalin for the treatment of FMS. Compared to placebo (PBO) Duloxetine (a serotonin norepinephrine reuptake inhibitor) and Pregabalin (an alpha-2-alpha-subunit calcium-channel ligand) significantly improved pain responses and fatigue. The capacity of Duloxetine to increase central levels of serotonin and norepinephrine as well as the more complex alterations of neurotransmitters and central nervous system (CNS) mediators of pain attributed to pregabalin are thought to be responsible for the medication's effects on pain, mood and sleep. Clinical practice and one open-label trial support the use of these medications in combination to achieve optimal symptom improvement amongst GWI sufferers; however, such combinations have not been formally tested in randomized controlled trials. The lack of progress in finding effective treatments for GWI, and the similarities between GWI and FMS, provides a rationale for determining if these FDA approved medications can provide significant symptomatic relief to Veterans who suffer from GWI. Central Texas is home to one of the highest number of Gulf War Veterans in the nation, thus the investigators' research team is ideally situated to conduct the proposed study. In a randomized, double-blind, controlled trial, 180 Veterans who meet defining criteria for GWI and whose symptom profile includes chronic widespread pain and sleep disturbances will be treated with one of the following medications; 1) AM Duloxetine+ PM placebo (PBO); 2) PM Pregabalin + AM PBO or 3) AM PBO + PM PBO. All active treatments will titrate from a lower dose in 2-week increments to the full therapeutic doses (FDA-approved for FMS). The outcome of the PBO double-dummy period will be compared statistically with 18 weeks of active therapy (weeks 5-22).


Recruitment information / eligibility

Status Terminated
Enrollment 112
Est. completion date August 1, 2019
Est. primary completion date August 1, 2019
Accepts healthy volunteers No
Gender All
Age group 44 Years to 70 Years
Eligibility Inclusion Criteria: - Living in Central Texas near Killeen, Austin, Temple or Waco - Served on active military duty and deployed to the Persian Gulf region for some period between August 1990 & July 1991 - English speaking and able to understand the consent form and study questionnaires - Willing to be randomized to treatment and participate in 1-month follow up - men & women between the ages of 43 to 70 - meet Kansas GWI case definition for the diagnosis of GWI - report a baseline score > 4 on a 10-point Pain Visual Analog Scale (VAS) - female participants of childbearing potential must test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use a reliable method of birth control (for example, oral contraceptives or Norplant; a reliable barrier method of birth control [diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam); intrauterine devices; partner with vasectomy; or abstinence) during the study and for 2 months following the last dose of the study drug. [Note that this inclusion criterion applies only to females of childbearing potential. Females of childbearing potential are defined as women not surgically sterilized and between menarche and 2 years post-menopause.] Exclusion Criteria: - Unstable or poorly controlled chronic medical illness such as Diabetes type-II, Hypertension (HTN), heart disease, endocrine disorders, narrow angle glaucoma - Significant Central Nervous System disease including transient ischemic attacks (TIAs) or stroke, Dementia, syncopal episodes, severe head trauma, multiple sclerosis - Serious or advanced heart disease or clinically relevant abnormal electrocardiogram (ECG), postural hypotension - Untreated sleep apnea or body mass index placing patients at risk for undiagnosed sleep apnea (BMI> 35 kg/m2) - Diabetes type-I and patients with Diabetes type-II associated with peripheral neuropathy, hepatitis, liver failure/cirrhosis - End stage renal disease - History of hypersensitivity reaction to pregabalin, duloxetine, venlafaxine; active treatment with duloxetine or pregabalin; History of failure of duloxetine or pregabalin at therapeutic doses; history of angioedema reaction to pregabalin - Active systemic infectious disease such as tuberculosis and HIV, shingles - Autoimmune mediated illnesses such as systemic lupus erythematosis, rheumatoid arthritis, scleroderma - History of mental illness requiring hospitalization (depression, bipolar illness, post traumatic stress disorder, history of suicide attempts, psychosis, schizophrenia spectrum); Current major depression of dysthymia; patients lacking capacity to make medical decisions - Use of monoamine oxidase inhibitors (MAOIs) within 2 weeks of evaluation; Active ongoing use of the following agents: desvenlafaxine, fenfluramine, linezolid, milnacipran, phentermine, tryptophan, tramadol, opiates - Current (meets criterion within the last 6 months) for drug or alcohol dependence (except for nicotine and caffeine) - Cancer other than non-melanoma skin cancers - Women who are pregnant or desire to become pregnant, breastfeeding, who use unreliable contraception methods - Those with occupations requiring use and/or operation of hazardous heavy equipment or professional drivers - Patients for whom the potential risk outweighs the potential benefit in the opinion of the treating psychiatrist

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Duloxetine
serotonin norepinephrine reuptake inhibitor
Pregabalin
alpha-2-alpha subunit calcium channel ligand
Placebo
Placebo

Locations

Country Name City State
United States Central Texas Veterans Health Care System, Temple, TX Temple Texas
United States Central Texas Veterans Health Care System Waco VA Medical Center, Waco, TX Waco Texas

Sponsors (2)

Lead Sponsor Collaborator
VA Office of Research and Development Texas A&M University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Multiple and Unreliable Reliability of measurement is highly suspect and data are not suitable for analysis. Assessed every 2 weeks up to 34 weeks
Primary Pain by Likert Scale Likert scale of pain rating 120 days
Secondary Side Effects Side effects checklist Assessed every 2 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04254627 - TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset Phase 1
Terminated NCT02011542 - Probiotic (VSL #3) for Gulf War Illness Phase 2/Phase 3
Recruiting NCT03078530 - Probiotic (Visbiome) for Gulf War Illness Phase 2/Phase 3
Recruiting NCT04058275 - "Immunomodulation in GWI (Phlebotomy)"
Recruiting NCT04255498 - Understanding GWI: Integrative Modeling Phase 1
Completed NCT02782780 - Cognitive Behavioral Therapy for Insomnia for Gulf War Illness N/A
Recruiting NCT02983734 - D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS) Phase 2
Recruiting NCT05972291 - Mechanisms of Gulf War Illness N/A
Recruiting NCT04046536 - rTMS in Alleviating Pain and Co-Morbid Symptoms in Gulf War Veterans Illness (GWVI) N/A
Recruiting NCT04182659 - Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms N/A
Recruiting NCT05377242 - Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI N/A
Recruiting NCT05675878 - Confirmation of Diet as a Treatment for Gulf War Illness Phase 3
Recruiting NCT05736146 - Validating Gulf War Illness Blood Biomarkers
Not yet recruiting NCT05820893 - Resistant Potato Starch to Alleviate GWI Phase 2
Active, not recruiting NCT05252949 - OEA for Targeting Lipid Metabolism in GWI N/A
Completed NCT02378025 - Treating Chronic Pain in Gulf War Illness N/A
Completed NCT02865460 - Coenzyme Q10 Phase III Trial in Gulf War Illness Phase 3
Completed NCT02909686 - Effects of Botanical Microglia Modulators in Gulf War Illness N/A
Completed NCT01291758 - Exercise in Gulf War Illness (GWI)
Completed NCT01011348 - Q10 for Gulf War Veterans N/A